Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Naurif
Other strengths and forms by Square Pharmaceuticals PLC, Pabna
Indications & Uses
Naurif is indicated for:
Pharmacology
Granisetron is a potent, selective antagonist of 5-HT3 receptors. It produces its antiemetic effect by blocking 5-HT3 receptors both centrally, in the medullary chemoreceptor zone, and peripherally, in the GI tract. Blocking these receptors in turn suppresses visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
For emetogenic chemotherapy, the recommended adult oral dose is 2 mg once daily or 1 mg twice daily. With the 2 mg once-daily regimen, two 1 mg tablets are taken up to one hour before chemotherapy. With the 1 mg twice-daily regimen, the first 1 mg tablet is taken up to one hour before chemotherapy and the second tablet 12 hours after the first. Either regimen is used only on the day(s) chemotherapy is given, and no dosage adjustment is required for elderly, renal failure, or hepatically impaired patients.
For radiation-induced nausea and vomiting, whether from total body irradiation or fractionated abdominal radiation, the recommended adult oral dose is 2 mg once daily, taken as two 1 mg tablets within one hour of irradiation. There is no experience with oral Granisetron for preventing radiation-induced nausea and vomiting in pediatric patients.
Dosage for other forms (1)
For chemotherapy-induced nausea and vomiting in adults, the recommended dose is 10 mcg/kg given intravenously within 30 minutes before chemotherapy is started, and only on the day(s) chemotherapy is given. It may be given intravenously either undiluted over 30 seconds or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Granisetron Injection should not be mixed in solution with other drugs. In pediatric patients 2 to 16 years of age, the recommended dose is also 10 mcg/kg; pediatric patients under 2 years of age have not been studied. In geriatric patients, renal failure patients, or hepatically impaired patients, no dosage adjustment is required.
For the treatment of postoperative nausea and vomiting in adults, the recommended dose for prevention is a single 1 mg dose of Granisetron diluted to 5 ml and given as a slow intravenous injection over 30 seconds, with administration completed before induction of anesthesia. For treating nausea and vomiting that has already occurred after surgery, the recommended dose is 1 mg of Granisetron given undiluted, intravenously, over 30 seconds. The safety and effectiveness of Granisetron Injection for preventing or treating postoperative nausea or vomiting have not been established in pediatric patients. As with the chemotherapy indication, no dosage adjustment is required in geriatric patients, renal failure patients, or hepatically impaired patients.
Side Effects
Granisetron can cause headache, constipation, weakness (asthenia), diarrhoea, abdominal pain, indigestion (dyspepsia), nausea and vomiting, dizziness, insomnia, and anxiety.
Cautions & Contraindications
Warnings & Precautions
Take care in patients who have heart conditions, who are on cardiotoxic chemotherapy, or who have electrolyte abnormalities at the same time. Granisetron may mask progressive ileus and/or gastric distention. Care is also needed in children, and during pregnancy and lactation.
Contraindications
Granisetron should not be used by anyone who is hypersensitive to it or to any of the other ingredients in its formulation.
Pregnancy & Breastfeeding
Pregnancy category B. Studies in animals have shown no evidence of impaired fertility or harm to the fetus. Even so, this medicine should be used during pregnancy only if clearly needed. It is not known whether granisetron passes into human breast milk, so caution should be exercised when giving it to a nursing mother.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Pediatric uses: the safety and effectiveness of Granisetron in children under 2 years of age have not been established.
Geriatric use: in older patients, efficacy and safety were maintained as age increased.
Storage
Granisetron injection: store below 25°C and protect from light. Tablet: store below °C and protect from light.
Common questions about Naurif 1 mg
What is Naurif 1 mg Tablet?
Naurif 1 mg Tablet is a medicine that contains Granisetron. It is made by Square Pharmaceuticals PLC, Pabna. It belongs to the Anti-emetic drugs group of medicines.
What is Naurif used for?
Naurif is used for: Nausea and Vomiting, Cancer.
What are the side effects of Naurif?
Granisetron can cause headache, constipation, weakness (asthenia), diarrhoea, abdominal pain, indigestion (dyspepsia), nausea and vomiting, dizziness, insomnia, and anxiety.
Can I take Naurif during pregnancy or while breastfeeding?
Pregnancy category B. Studies in animals have shown no evidence of impaired fertility or harm to the fetus. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Naurif?
Granisetron injection: store below 25°C and protect from light. Tablet: store below °C and protect from light.
Is there a cheaper medicine with the same ingredient?
Naurif is already among the lowest-priced brands of Granisetron at this strength.
Do I need a prescription for Naurif?
Naurif is a prescription (Rx) medicine. Take it as your doctor advises.